Parkwoods Wealth Partners’s AbbVie ABBV Stock Holding History

Parkwoods Wealth Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$362K	Buy	1,441 +362	+34%	+$77.9K	0.06%	120
2026 Q1	$235K	Buy	+1,079	New	+$239K	0.06%	96

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Parkwoods Wealth Partners's ABBV Position: Q2 2026 in Review

Parkwoods Wealth Partners increased its AbbVie (ABBV) stake by 34% in Q2 2026, buying an estimated $77.9K and bringing the position to 1,441 shares worth $362K. The position accounts for 0.06% of the portfolio, ranked #120.

Parkwoods Wealth Partners first reported a position in ABBV in Q1 2026 and has held it in 2 quarters since. 4,222 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Parkwoods Wealth Partners held 1,441 shares of AbbVie worth $362K as of Q2 2026.
Parkwoods Wealth Partners bought 362 AbbVie shares in Q2 2026, an estimated $77.9K.
AbbVie made up 0.06% of Parkwoods Wealth Partners's portfolio in Q2 2026, its #120 holding.
Parkwoods Wealth Partners first reported a position in AbbVie in Q1 2026 and has held it in 2 quarters since.
4,222 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Parkwoods Wealth Partners's 13F filing for Q2 2026, filed 27 Jul 2026.